Xenon Pharmaceuticals (NASDAQ:XENE) and BioXcel Therapeutics (NASDAQ:BTAI) are two medical companies that have garnered attention in the investment world. In this article, we will compare the two businesses based on various factors such as profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, and risk.
According to MarketBeat, analysts have provided ratings and target prices for both Xenon Pharmaceuticals and BioXcel Therapeutics. Xenon Pharmaceuticals currently has a consensus price target of $58.78, indicating a potential upside of 46.40%. On the other hand, BioXcel Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 853.87%. Analysts seem to favor BioXcel Therapeutics due to its higher possible upside.
When it comes to valuation and earnings, BioXcel Therapeutics has lower revenue but higher earnings compared to Xenon Pharmaceuticals. Additionally, Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, making it the more affordable stock at present.
Institutional and insider ownership also play a role in evaluating these companies. 95.5% of Xenon Pharmaceuticals shares are held by institutional investors, while only 30.7% of BioXcel Therapeutics shares are held by institutional investors. Furthermore, 5.5% of Xenon Pharmaceuticals shares are held by insiders, whereas 35.8% of BioXcel Therapeutics shares are held by insiders. Strong institutional ownership is often seen as an indication of long-term growth potential.
Profitability is another important aspect to consider. Comparing net margins, return on equity, and return on assets, Xenon Pharmaceuticals outperforms BioXcel Therapeutics on 10 out of 15 factors.
In terms of volatility and risk, Xenon Pharmaceuticals has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Conversely, BioXcel Therapeutics has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500.
In summary, based on the available data, Xenon Pharmaceuticals appears to have an edge over BioXcel Therapeutics in several areas. However, it is important for investors to conduct further research and consider their own investment strategies before making any decisions.
Xenon Pharmaceuticals, headquartered in Burnaby, Canada, is a clinical-stage biopharmaceutical company focused on developing therapeutics for neurological disorders. Its product pipeline includes XEN496 and XEN1101, among others. The company has a license and collaboration agreement with Neurocrine Biosciences Inc.